deferoxamine mesylate


Also found in: Wikipedia.

de·fer·ox·a·mine mes·y·late

(de'fĕr-ok'să-mēn mes'i-lāt),
Chelate used to treat iron poisoning; also chelates aluminum.

deferoxamine mesylate

[dē′fərok′səmēn]
a chelating agent with specific affinity for ferric iron and low affinity for calcium.
indications It is prescribed in the treatment of acute iron intoxication and chronic iron overload.
contraindications Renal disease or anuria prohibits its use.
adverse effects Among the most serious adverse reactions are hypotension, tachycardia, dysuria, visual difficulties, and anaphylactoid reactions.

deferoxamine mesylate

(dĕ-fĕr-ŏks′ă-mēn)
A drug with a very high affinity for iron. It is used parenterally to reduce the iron overload in patients with hemochromatosis, acute iron poisoning, or multiple blood transfusions.
References in periodicals archive ?
In treatment group 3, birds were treated with deferoxamine mesylate (100 mg/kg SC q24h; Desferal, Novartis Pharmaceuticals Corp, East Hanover, N J, USA) in addition to the low-iron diet.
The chief problem with deferoxamine mesylate therapy is that patients sometimes skip treatments, notes Stanley L.
Researchers in Italy compared deferoxamine mesylate with ICL670 in 71 patients with an average age of 25.
Periodic testing of iron content in the patients' blood and liver over a year showed that ICL670 cleared transfusion-caused iron overload as well as deferoxamine mesylate did, says study coauthor Antonio Piga of Turin University.
Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths.
APP will package Deferoxamine Mesylate in single dose vials of 500 mg, 10 mL and 2 gram, 30 mL.
Deferoxamine Mesylate is an iron chelating agent that is used for iron poisoning as well as chronic iron overload due to transfusion-dependent anemias.
APP plans to launch Deferoxamine Mesylate in the fourth quarter of 2009, which will further expand the company's critical care product line.
Food and Drug Administration has granted approval for the Company's ANDA for Deferoxamine Mesylate for Injection USP, 500 mg/vial and 2 g/vial.
Teva's Deferoxamine Mesylate for Injection is the AP-rated generic equivalent of Novartis' Desferal(R) for Injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias.
Total annual sales of Deferoxamine Mesylate for Injection are approximately $43 million.